Cyclosporine
- Generic Name
- Cyclosporine
- Brand Names
- Cequa, Gengraf, Neoral, Restasis, Sandimmune, Verkazia, Vevye, Ikervis
- Drug Type
- Small Molecule
- Chemical Formula
- C62H111N11O12
- CAS Number
- 59865-13-3
- Unique Ingredient Identifier
- 83HN0GTJ6D
- Background
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus Beauveria nivea. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).
- Indication
Cyclosporine is approved for a variety of conditions. Firstly, it is approved for the prophylaxis of organ rejection in allogeneic kidney, liver, and heart transplants. It is also used to prevent bone marrow transplant rejection. For the above indications, cyclosporine can be used in conjunction with azathioprine and corticosteroids. Finally, cyclosporine can be used in patients who have chronic transplant rejection and have received previous immunosuppressive therapy and to prevent or treat graft-versus-host disease (GVHD).
Secondly, cyclosporine is used for the treatment of patients with severe active rheumatoid arthritis (RA) when they no longer respond to methotrexate alone. It can be used for the treatment of adult non-immunocompromised patients with severe, recalcitrant, plaque psoriasis that have failed to respond to at least one systemic therapy or when systemic therapies are not tolerated or contraindicated. The ophthalmic solution of cyclosporine is indicated to increase tear production in patients suffering from keratoconjunctivitis sicca. In addition, cyclosporine is approved for the treatment of steroid dependent and steroid-resistant nephrotic syndrome due to glomerular diseases which may include minimal change nephropathy, focal and segmental glomerulosclerosis or membranous glomerulonephritis.
A cyclosporine ophthalmic emulsion is indicated in the treatment of vernal keratoconjunctivitis in adults and children.
Off-label, cyclosporine is commonly used for the treatment of various autoimmune and inflammatory conditions such as atopic dermatitis, blistering disorders, ulcerative colitis, juvenile rheumatoid arthritis, uveitis, connective tissue diseases, as well as idiopathic thrombocytopenic purpura.
- Associated Conditions
- Atopic Dermatitis, Bone Marrow Transplant Rejection, Chronic transplant rejection, Connective Tissue Disorders, Dry Eyes, Graft-versus-host Disease (GVHD), Heart Transplant Rejection, Immune Thrombocytopenia (ITP), Interstitial Cystitis, Juvenile Idiopathic Arthritis (JIA), Kidney Transplant Rejection, Liver Transplant Rejection, Lupus Nephritis, Nephrotic Syndrome, Ocular Rosacea, Rheumatoid Arthritis, Severe Ulcerative Colitis, Steroid Dependent Nephrotic Syndrome, Steroid Resistant Nephrotic Syndrome, Uveitis, Vernal Keratoconjunctivitis, Blistering disorder, Refractory Ulcerative colitis, Severe Psoriasis, Severe, active Rheumatoid arthritis, Severe, recalcitrant Plaque psoriasis, Suppressed tear production
- Associated Therapies
- -
Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer
- Conditions
- Acute Undifferentiated LeukemiaAdult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)AIDS-related Immunoblastic Large Cell LymphomaChildhood Acute Lymphoblastic Leukemia in RemissionChildhood Immunoblastic Large Cell LymphomaChildhood Myelodysplastic SyndromesChildhood Nasal Type Extranodal NK/T-cell LymphomaChronic Neutrophilic Leukemia
- Interventions
- First Posted Date
- 2005-06-03
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 5
- Registration Number
- NCT00112593
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma
- Conditions
- Interventions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- The Hospital for Sick Children
- Target Recruit Count
- 71
- Registration Number
- NCT00110110
- Locations
- 🇨🇱
Hospital San Juan de Dios, Santiago, Chile
🇨🇦Children's and Women's Hospital of British Columbia, Vancouver, British Columbia, Canada
🇮🇳Sankara Nethralaya Super Specialty Clinic, Chennai, India
Fludarabine and Radiation Therapy in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Phase or Accelerated Phase Chronic Myelogenous Leukemia
- Conditions
- First Posted Date
- 2005-05-04
- Last Posted Date
- 2011-11-17
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT00110058
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Immune System Suppression With Alemtuzumab and Tacrolimus in Liver Transplantation Patients
- First Posted Date
- 2005-03-11
- Last Posted Date
- 2012-12-27
- Target Recruit Count
- 27
- Registration Number
- NCT00105235
- Locations
- 🇺🇸
University of Miami School of Medicine, Miami, Florida, United States
🇺🇸University of California, San Francisco, San Francisco, California, United States
🇺🇸University of Michigan, Ann Arbor, Michigan, United States
Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Conditions
- Chronic Lymphocytic LeukemiaRefractory Chronic Lymphocytic LeukemiaStage III Small Lymphocytic LymphomaStage IV Small Lymphocytic LymphomaProlymphocytic LeukemiaStage III Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaStage IV Chronic Lymphocytic LeukemiaT-Cell Large Granular Lymphocyte Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationDrug: CyclosporineDrug: Fludarabine PhosphateOther: Laboratory Biomarker AnalysisDrug: Mycophenolate MofetilProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyBiological: RituximabRadiation: Total-Body Irradiation
- First Posted Date
- 2005-03-04
- Last Posted Date
- 2019-07-11
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT00104858
- Locations
- 🇺🇸
VA Puget Sound Health Care System, Seattle, Washington, United States
🇩🇰Rigshospitalet University Hospital, Copenhagen, Denmark
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
Pentostatin and Lymphocyte Infusion in Preventing Graft Rejection in Patients Who Have Undergone Donor Stem Cell Transplant
- Conditions
- Interventions
- First Posted Date
- 2004-11-09
- Last Posted Date
- 2020-01-31
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 36
- Registration Number
- NCT00096161
- Locations
- 🇺🇸
LDS Hospital, Salt Lake City, Utah, United States
🇺🇸VA Puget Sound Health Care System, Seattle, Washington, United States
🇮🇹University of Torino, Torino, Italy
Antithymocyte Globulin and Cyclosporine in Preventing Graft-Versus-Host Disease in Patients Undergoing Chemotherapy With or Without Radiation Therapy Followed By Donor Stem Cell Transplant for Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2013-11-06
- Lead Sponsor
- Jonsson Comprehensive Cancer Center
- Registration Number
- NCT00093587
- Locations
- 🇺🇸
Jonsson Comprehensive Cancer Center at UCLA, Los Angeles, California, United States
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed by Unrelated Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia
- Conditions
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Fanconi AnemiaAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Childhood Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With t(16;16)(p13;q22)Childhood Myelodysplastic Syndromes
- Interventions
- First Posted Date
- 2004-10-08
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 2
- Registration Number
- NCT00093743
- Locations
- 🇺🇸
Riley Hospital for Children, Indianapolis, Indiana, United States
🇺🇸Robert H. Lurie Comprehensive Cancer Center, Chicago, Illinois, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Newly Diagnosed Brain Stem Glioma
- Conditions
- Interventions
- First Posted Date
- 2004-09-13
- Last Posted Date
- 2014-07-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 7
- Registration Number
- NCT00003625
- Locations
- 🇺🇸
Baptist Hospital of Miami, Miami, Florida, United States
🇺🇸Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Lucile Packard Children's Hospital at Stanford, Palo Alto, California, United States
Prevention of Graft-Versus-Host Disease in Patients With Hematologic Malignancies Who Are Receiving a Bone Marrow Transplant
- Conditions
- First Posted Date
- 2004-09-02
- Last Posted Date
- 2015-03-06
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Registration Number
- NCT00002790
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.